Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.
加利福尼亞州海沃德，2024年5月1日（GLOBE NEWSWIRE）——貝尼特克生物製藥公司（納斯達克股票代碼：BNTC）（“貝尼特克” 或 “公司”）是一家臨床階段、專注於基因療法的生物技術公司，基於其專有的 “沉默與替換” DNA導向RNA干擾（“ddrNAI”）平台開發新型基因藥物，今天宣佈，貝尼特克的成員管理層將參加2024年5月13日至14日在紐約州紐約舉行的Citizens JMP生命科學會議。
Presentation Details:
Date: May 13, 2024
Time: 11:00 am EDT
Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer
演示詳情：
日期：2024 年 5 月 13 日
時間：美國東部時間上午 11:00
主持人：傑瑞爾·班克斯，醫學博士，執行董事長兼首席執行官
The Benitec presentation will also be available via live webcast here.
Benitec的演示也將通過此處的網絡直播播出。
Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.
請聯繫您的Citizens JMP代表，安排與貝尼特克管理層的1x1會議。
About Benitec Biopharma Inc.
關於 Benitec Biopharma Inc.
Benitec Biopharma Inc. ("Benitec" or the "Company") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary "Silence and Replace" DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec's website at .
Benitec Biopharma Inc.（“Benitec” 或 “公司”）是一家臨床階段的生物技術公司，專注於新型基因藥物的發展，總部位於加利福尼亞州海沃德。專有的 “Silence and Replace” 以DNA爲導向的RNA干擾平台將RNA干擾（RNAi）與基因療法相結合，開發出能夠同時促進致病基因持續沉默的藥物，同時促進單一施用該治療結構後野生型替代基因的傳遞。該公司正在開發基於Silence and Replace的療法，用於治療慢性和危及生命的人體疾病，包括眼嚥肌萎縮症（OPMD）。公司的全面概述可以在Benitec的網站上找到，網址爲。
Investor Relations Contact:
投資者 關係 聯繫人：
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
伊琳娜·科夫勒
生命科學顧問
電話：(917) 734-7387
ikoffler@lifesciadvisors.com
譯文內容由第三人軟體翻譯。